A decade of targets and patented drugs for chemotherapy of chagas disease

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 3, 2011, Pages 216-259

  Duschak, Vilma G ^a  

^a Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

Author keywords

Chagas disease; Drug targets; Patents; Trypanosoma cruzi

Indexed keywords

1 (PYRIDINE 2 YLSULFONYL)AZEPAN 3 ONE DERIVATIVE; 2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; AJOENE; ALBACONAZOLE; AMIODARONE; BIS ARYLACYLHYDRAZIDE DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL ALLYL SULPHONE DERIVATIVE; DIPHENYLAMINE DERIVATIVE; ITRACONAZOLE; K 11777; KETOCONAZOLE; N ALKOXYVINYLSULFONAMIDE INHIBITOR; N METHYL PIP F HOMO F VINYL SULFONYLUREA PHENYL; NITRILE; NITROFURAL; PAMIDRONIC ACID; PEPTIDYL DIAZOMETHANE INHIBITOR; PEPTIDYL KETONE INHIBITOR; PEPTIDYL VINYL SULPHONE; POSACONAZOLE; QUINOLONE DERIVATIVE; RAVUCONAZOLE; RISEDRONIC ACID; SALINOSPORAMIDE A; THIOSEMICARBAZONE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; WRR 483;

ARTICLE; CALCIUM BINDING; CHAGAS DISEASE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GLYCOLYSIS; HOST PARASITE INTERACTION; HUMAN; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PATENT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ANIMALS; CHAGAS DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; PATENTS AS TOPIC; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 80052825043     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796887864     Document Type: Article

References (410)

1. Estimación cuantitativa de la Enfermedad de Chagas en las Américas Organización Panamericana (OPS) de la Salud. Geneva. Ref type Pamphlet. Department of control of Neglected Tropical dis eases (NTD). OPS/HDM/CD/425; 2006:1-28
2. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: A review. Mem Inst Oswaldo Cruz 2002; 97(5): 603-12.
3. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005; 18(1): 12-29.
4. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: The role of international migration Mem Inst Oswaldo Cruz, Rio de Janeiro 2007; 102(Suppl. I): 75-85.
5. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010; 115(1-2): 22-7.
6. Barbosa PR. The oral transmission of Chagas disease: An acute form of infection responsible for regional outbreaks. Int J Cardiol 2006; 112: 132-3.
7. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States: A systematic review. JAMA 2007; 298: 2171-81.
8. Alarcón de Noya B, Diaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Zavala-Jaspe R, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas,Venezuela. J Infect Dis 2010; 201(9):1308-15.
9. Matsumoto SC, Labovsky V, Roncoroni M, Guida MC, Gimenez L, Mitelman J, et al. Retinal dysfunction in patients with chronic Chagas' disease is associated to anti-Trypanosoma cruzi antibodies that cross-react with rhodopsin. FASEB J 2006; 20(3): 550-2.
10. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Lu-quetti A, Travassos LR, et al. Randomised trial of efficacy of ben-randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348: 1407-13.
11. Sosa ES. Treatment of Trypanosoma cruzi infection in the unde termined phase. Experience and guidelines of treatment in Argen tina. Mem Inst Oswaldo Cruz 1999; 94 (Suppl. I): 363-5.
12. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 2007; 102 (Suppl. I): 95-7.
13. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, Spray DC, et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 2009; 51: 524-39.
14. Rodriques CJ, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97 (1): 3-24. Review.
15. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. Longitudinal study and specific chemotherapy in children with chronic Chagas disease residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 2004; 37: 365-75.
16. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Ami-cone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: Parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40: 1-10.
17. Garcia S, Ramos CO, Senra JFV, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents Chemother 2005; 49(4): 1521-8.
18. de Mecca MM, Bartel LC, de Castro RC, Castro JA. Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to nifurtimox-induced cardiac effects. Mem Inst Oswaldo Cruz, Rio Janeiro 2008; 103(6): 549-53.
19. Apt W, Arribada A, Zulantay I, Solari A, Sanchez G, Mundaca K, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005; 99(8): 733-41.
20. Duschak VG, Couto AS. An insight on targets and patented drugs for chemotherapy of Chagas disease. Rec Pat Anti-Infec Drug Disc 2007; 2: 19-51.
21. Duschak VG, Couto AS. Targets and patented drugs for chemotherapy of Chagas disease. Frontiers in Anti-Infective Drug Discovery. Atta-ur-Rahman FRS /Choudhary MI (Eds.), Bentham Science Publishers, University of Karachi, Pakistan 2010; 1 (18):323-408.
22. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran A-H, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005; 309(5733): 409-15.
23. Cazzulo JJ, Stoka V, Turk V. The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas disease. Curr Pharm Des 2001; 7(12): 1143-56.
24. Cazzulo JJ, Cazzulo Franke BM, Martinez J, Franke de Cazzulo BM. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Byophys Acta 1990; 1037(2): 186-91.
25. Eakin AE, Mills AA, Harth G, McKerrow JH, Craik CS. The sequence, organization, and expression of the major cysteine prote-inase (cruzain) from Trypanosoma cruzi. J Biol Chem 1992; 267: 7411-20.
26. Murta ACM, Persechini PM, de Souto Padrón T, de Souza W, Guimaraes JA, Scharfstein J. Structural and functional identification GP57/51 antigen of Trypanosoma cruzi as a cysteine protein-ase. Mol Biochem Parasitol 1990; 43: 27-38.
27. dos Reis FC, Júdice WA, Juliano MA, Scharfstein J, Lima AP. The substrate specificity of cruzipain 2, a cysteine protease isoform from Trypanosoma cruzi. FEMS Microbiol Lett 2006; 259(2): 215-20.
28. Malchiodi EL, Chiaramonte MG, Martínez JA, Zwirner NW, Mar-gni RA, Cazzulo JJ. Identity of the major cysteine proteinase (cru-zipain) from Trypanosoma cruzi and an antigen (Ag163B6) isolated with a monoclonal antibody. Immunol Lett 1993; 35(1): 59-62.
29. Cazzulo JJ, Labriola C, Parussini F, Duschak VG, Martinez J, Franke de Cazzulo BM. Cysteine proteinases in Trypanosoma cruzi and other Trypanosomatid parasites. Acta Chim Slov 1995; 42: 409-18.
30. Souto-Padrón T, Campetella OE, Cazzulo JJ, de Souza W. Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction. J Cell Sci 1990; 96(3): 485-90.
31. Nascimento AE, de Souza W. High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Biol Cell 1996; 86(1): 53-8.
32. Parusini F, Duschak VG, Cazzulo JJ. Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypano-soma cruzi. Cell Mol Biol 1998; 44(3): 513-9.
33. Duschak VG, Barboza M, Garcia GA, Lammel EM, Couto AS, Isola EL. Novel cysteine proteinase in Trypanosoma cruzi metacy-clogenesis. Parasitology 2006; 132(3): 345-55.
34. Cazzulo JJ. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr Top Med Chem 2002; 2(11): 1261-71
35. Duschak VG, Ciaccio M, Nassert JR, Basombrio MA. Enzymatic activity, protein expression, and gene sequence of cruzipain in virulent and attenuated Trypanosoma cruzi strains. J Parasitol 2001; 87(5): 1016-22.
36. Ramos AM, Duschak VG, Gerez de Burgos NM, Barboza M, Remedi MS, Vides MA, et al. Trypanosoma cruzi: Cruzipain and membrane bound cysteine proteinase isoform(s) interacts with human alpha (2)-macroglobulin and pregnancy zone protein. Exp Parasitol 2002; 100(2): 121-30.
37. Duschak VG, Riarte A, Segura EL, Laucella SA. Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease. Immunol Lett 2001; 78(3): 135-42.
38. Barboza M, Duschak VG, Cazzulo JJ, Lederkremer RM, Couto AS. Presence of sialic acid in N-linked oligosaccharide chains and O-linked-N-acetylglucosamine in cruzipain, the major cysteine prote-inase of Trypanosoma cruzi. Mol Biochem Parasitol 2003; 126: 293-6.
39. Barboza M, Duschak VG, Fukuyama Y, Nonami H, Erra-Balsells R, Cazzulo JJ, et al. Structural analysis of the N-glycans of the major cysteine proteinase of Trypanosoma cruzi. Identification of sul-fated high-mannose type oligosaccharides. FEBS J 2005; 272(15): 3803-15.
40. Acosta DM, Arnaiz MR, Esteva MI, Barboza M, Stivale D, Orlando UD, et al. Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized mice. Int Immunol 2008; 20: 461-70.
41. Duschak VG, Couto AS. Cruzipain, the major cysteine protease of Trypanosoma cruzi: A sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr Med Chem 2009; 16: 3174-202.
42. Duschak VG, Barboza M, Couto AS. Trypanosoma cruzi: Partial characterization of minor cruzipain isoforms non-adsorbed to Con-canavalin A-Sepharose. Exp Parasitol 2003; 104(3-4): 122-30.
43. McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS, Fletterick RJ, et al. The crystal structure of cruzain: A therapeutic target for Chagas disease. J Mol Biol 1995; 247(2): 251-9.
44. Huang L, Brinen LS, Ellman JA. Crystal structures of reversible ketone-based inhibitors of the cysteine protease cruzain. Bioorg Med Chem 2003; 11(1): 21-9.
45. Kerr ID, Lee JH, Farady CJ, Marion R, Rickert M, Sajid M, et al. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem 2009; 284(38): 25697-703.
46. Yong V, Schmidtz V, Vannier-Santos MA, de Lima AP, Lalmanach G, Juliano L, et al. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases. Mol Biochem Parasitol 2000; 109(1): 47-59.
47. García MP, Nóbrega, OT, Teixeira, ARL, Sousa MV, Santana, JM. Characterization of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Mol Biochem Parasitol 1998; 91: 263-72.
48. Lalmanach G, Mayer R, Serveau C, Scharfstein J, Gauthier F. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: Targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem J 1996; 318: 395-9.
49. Hernandez AA, Roush WR. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr Opin Chem Biol 2002; 6(4): 459-65.
50. Engel JC, Doyle PS, Hsieh Y, McKerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998; 88(4): 725-34.
51. Engel JC, Doyle PS, Palmer J, Bainton DF, Hsieh I, McKerrow JH. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 1998; 11: 597-606.
52. McKerrow JH. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: Insights on safety, target validation, and mechanism of action. Int J Parasitol 1999; 29(6): 833-7.
53. Roush WR, Cheng J, Knapp-Reed B, Alvarez-Hernandez A, McKerrow JH, Hansell E, et al. Potent second generation vinyl sul-fonamide inhibitors of the Trypanosomal cysteine protease cruzain. Bioorg Med Chem Lett 2001; 11: 2759-62.
54. Gotz MG, Caffrey CR, Hansell E, Mc Kerrow JH, Powers JC. Peptidyl allyl sulfones: A new class of inhibitors for clan CA cys-teine proteases. Bioorg Med Chem 2004; 12(19): 5203-11.
55. Powers, J.C., Gotz, M.G. Peptidyl allyl sulfones. US7521427 (2005) & US7521427 (2009).
56. Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures chagas disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 2007; 51(11): 3932-9.
57. Chen YT, Lira R, Hansell E, McKerrow JH, Roush WR. Synthesis of macrocyclic Trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett 2008; 18(22): 5860-3.
58. Mc Kerrow JH, Doyle PS, Engel JC, Produst LM, Robertson SA, Ferreira R, et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst O. Cruz 2009; 104 (Suppl 1): 263-9.
59. Chen YT, Brinen LS, Kerr ID, Hansell E, Doyle PS, McKerrow JH, et al. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. Plos Negl Trop Dis 2010; 4(9) pii: e825.
60. Li R, Chen X, Gong B, Selzer PM, Li Z, Davidson E, et al. Structure-based design of parasitic protease inhibitors. Bioorg Med Chem 1996; 4(9): 1421-7.
61. Du X, Hansell E, Engel JC, Caffrey CR, Cohen FE, McKerrow JH. Aryl ureas represent a new class of anti-trypanosomal agents. Chem Biol 2000; 7(9): 733-42.
62. Huang L, Lee A, Ellman JA. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J Med Chem 2002; 45(3): 676-84.
63. Choe Y, Brinen LS, Price MS, Engel JC, Lange M, Grisostomi C, et al. Development of alpha-keto-based inhibitors of cruzain, a cys-teine protease implicated in Chagas disease. Bioorg Med Chem 2005; 13(6): 2141-56.
64. Marquis, R.W., Ru, Y., Veber, D.F., Cummings, M., Thompson, S.K., Yamashita, D. Protease inhibitors. WO200195911 (2001).
65. Quibell, M., Taylor, S., Grabowska, U., Nilsson, M., Morrison, V. Cysteine protease inhibitors. WO20020240462 (2002).
66. Quibell, M., Ramjee, M.K. Inhibitors of cruzipain and other cys-teine proteases. WO2002057246 (2002).
67. Quibell, M. Inhibitors of cruzipain and other cysteine proteases. WO2002057248A2/A3 (2002), WO2002057249A1 (2002), WO02057270A1 (2002), CA2436462 (2002).
68. Quibell, M. Inhibitors of cruzipain and other cysteine proteases. EP1362052A1 (2003), NO20033220A/A0 (2003).
69. Quibell, M. Inhibitors of cruzipain and other cysteine proteases. CN1486320A (2004), MX3006224A (2004), ZA0305259A (2004). NZ0526913 (2004).
70. Quibell, M., Ray, P.C. Watts, J.P. Biologically active compounds. WO2004007501 (2004).
71. Lim-Wilb, M., Semple, J.E., Araldi, G.L., Goldman, E.A., Wein house, M.I. Compounds, compositions and methods for treatment of parasitic infections. WO200248097A1 (2002), WO200348097B1/C2 (2003).
72. Quibell, M., Ramjee, M.K. Inhibitors of cruzipain and other cys-teine proteases. US6958358 (2005).
73. Quibell, M. Inhibitors of cruzipain and other cysteine proteases. US7425562 (2008).
74. Marquis, R.W., Jr, Veber, D.F., Yamashita, D.S. Protease inhibitors. WO2003053331A2/A3 (2003)
75. Jeong, J.U.; Yamashita, D.S. Protease inhibitors. WO2003097593A2/A3 (2003), WO2003104257A2/A3 (2003)
76. Tew, D.G., Thompson, S.K., Veber, D.F. Method of treatment. WO200217924A1 (2002).
77. Altman, E., Betschart, C., Hayakawa, K., Irie, O., Sakaki, J., Iwa-saki, G., Lattmann, R., Missbach, M., Teno, N. Hetereoaryl nitrile derivatives. WO2004020441A1 (2004).
78. Bondebjerg, J., Fuglsang, H., Naerum, L. Protease inhibitors. WO2004110988A1 (2004).
79. Hickey, E.R., Bekkali, Y., Patel, U.R., Spero, D.M., Thomson, D.S., Young, E.R. Novel nitriles useful as reversible inhibitors of cysteine proteases. WO2002100849 (2002), US6982263 (2006).
80. Sulea, T., Purisima, E.O., Menard, R., Wang, J. Propeptide-based inhibitors of cysteine proteases. WO2003097664A2/A3 (2003).
81. Beaulieu C, Isabel E, Fortier A, Massé F, Mellon C, Méthot N, et al. Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease. Bioorg Med Chem 2010; 20(24): 7444-9.
82. Mott BT, Ferreira RS, Simeonov A, Jadhav A, Kean-Hooi K, Leister W, et al., Identification and optimization of inhibitors of Trypanosomal cysteine proteases: Cruzain, rhodesain, and TbCatB. J Med Chem 2010; 53(1): 52-60.
83. Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, et al. Synthesis and structure-activity relationship study of potent try-panocidal thio semicarbazone inhibitors of the Trypanosomal cys-teine protease cruzain. J Med Chem 2002; 45(13): 2695-7.
84. Chibale K, Musonda CC. The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. Curr Med Chem 2003; 10(18): 1863-89.
85. Chiyanzu I, Hansell E, Gut J, Roshenthal PJ, McKerrow JH, Chibale K. Synthesis and evaluation of isatins and thiosemicarba-zone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett 2003; 13(20): 3527-30.
86. Fujii N, Mallari JP, Hansell EJ, Mackey Z, Doyle P, Zhou YM, et al. Discovery of potent thiosemicarbazone inhibitors of rhode-sain and cruzain. Bioorg Med Chem Lett 2005; 15(1): 121-3.
87. Engel JC, Garcia CT, Hsieh I, Doyle PS, McKerrow JH. Upregula-tion of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi. J Cell Sci 2000; 113: 1345-54.
88. Desai PV, Patny A, Sabnis Y, Tekwani B, Gut J, Rosenthal P, et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening 1. The Chem Bridge database. J Med Chem 2004; 47(26): 6609-15.
89. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49(12): 5160-1.
90. Greenbaun DC, McMackey Z, Hansell E, Doyle P, Gut J, Caffrey CR, Lehrman J, et al. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Try-panosoma cruzi. J Med Chem 2004; 47(12): 3212-9.
91. Cohen, F.E., Du, X., Guo, Ch., McKerrow, J.H. Thio semicarba-zone and semicarbazone inhibitors of cysteine proteases and methods of their use. US6897240 (2005), US7495023 (2009).
92. Aguirre G, Boiani L, Cerecetto H, Fernández M, González M, Denicola A, et al. In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorg Med Chem 2004; 12(18): 4885-93.
93. Otero L, Maya JD, Morello A, Insight into the bioreductive mode of action of anti-trypanosomal 5-nitrofuryl containing thiosemicar-bazones. Med Chem 2008; 4(1): 11-17.
94. Leite AC, de Lima RS, Moreira DR, Cardoso MV, Gouveia de Brito AC, Farias Dos Santos LM, et al. Synthesis, docking, and in vitro activity of thiosemicarbazones, aminoacyl-thiosemicarbazides and acyl-thiazolidones against T. cruzi. Bioorg Med Chem 2006; 14(11): 3749-57.
95. Leite AC, Moreira DR, Cardoso MV, Hernandes MZ, Alves Perei-ra VR, Silva RO, et al. Synthesis, cruzain docking, and in vitro studies of aryl-4-oxothiazolylhydrazones against Trypanosoma cruzi. Chem Med Chem 2007; 2(9): 1339-45.
96. Porcal W, Hernandez P, Boiani M, Aguirre G, Boiani L, Chidichimo A, et al. In vivo anti-Chagas vinylthio, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. J Med Chem 2007; 50(24): 6004-15.
97. Brak K, Doyle PS, McKerrow JH, Ellman JA. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 2008; 130(20): 6404-10.
98. Brak K, Kerr ID, Barrett KT, Fuchi N, Debnath M, Ang K, et al., Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem 2010; 53(4): 1763-73.
99. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, et al. Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 2008; 102(10): 1839-45.
100. Trossini GH, Malvezzi A, T-do Amaral A, Rangel-Yagui CO, Izidoro MA, Cezari MH, et al. Cruzain inhibition by hydroxymeth-ylnitrofurazone and nitrofurazone: investigation of a new target in Trypanosoma cruzi. J Enzyme Inhib Med Chem 2010; 25(1): 62-7.
101. Aguirre G, Cerecetto H, Di Maio R, González M, Alfaro ME, Jaso A, et al. Quinoxaline N, N'-dioxide derivatives and related compounds as growth inhibitors of T. cruzi. Structure-activity relationships. Bioorg Med Chem 2004; 14(14): 3835-9.
102. Romeiro NC, Aguirre G, Hernández P, González M, Cerecetto H, Aldana I, et al. Synthesis, trypanocidal activity and docking studies of novelquinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg Med Chem 2009; 17(2): 641-52
103. Ferreira RS, Bryant C, Ang KK, McKerrow JH, Shoichet BK, Renslo AR Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem 2009; 52(16): 5005-8.
104. 2+ concentration. J Physiol Biochem 2010; 66(4): 283-90.
105. Bourguignon SC, Castro HC, Santos DO, Alves CR, Ferreira VF, Gama IL, et al. Trypanosoma cruzi: In vitro activity of Epoxy-alpha-Lap, aderivative of alpha-lapachone, on trypomastigote and amastigote forms. Exp Parasitol 2009; 122(2): 91-6.
106. Bourguignon SC, Cavalcanti DF, de Souza AM. Trypanosoma cruzi: Insights into naphthoquinone effects on growth and protein-ase activity. Exp Parasitol 2011; 127(1): 160-6.
107. Redzynia I, Ljunggren A, Bujac Z, Abrahamson M, Jaskolski M, Bujacz G. Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases. FEBS J 2009; 276(3):793-806.
108. Sorimachi H, Hata S, Ono Y. Expanding members and roles of the calpain superfamily and their genetically modified animals. Exp Anim 2010; 59(5): 549-56.
109. Giese V, Dallagiovanna B, Mancini FK, Pavoni DP, Krieger MA, Goldenberg S. Trypanosoma cruzi: a stage-specific calpain-like protein is induced after various kinds of stress. Mem Inst O Cruz 2008; 103(6): 598-601.
110. Kosec G, Alvarez V, Cazzulo JJ. Cysteine proteinases of Trypano-soma cruzi: From digestive enzymes to programmed cell death mediators. Biocell 2006; 30(3): 479-90.
111. Sangenito LS, Ennes-Vidal, Marinho FA, Da Mota FF, Santos AL, D'Avila-Levy CM, et al. Arrested growth of Trypanosoma cruzi by the calpain inhibitor MDL28170 and detection of calpain homo-logues in epimastigote forms. Parasitology 2009; 136(10):1235-43.
112. Ennes-Vidal V, Menna Barreto RF, Santos AL, Branquinha MH, d'Avila-Levy CM. Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. J An-timicrob Chemother 2010; 65(7): 1395-8.
113. González IJ. Las metacaspasas y su rol en la vida y muerte de los parásitos protozoarios humanos. Biomédica 2009; 29: 485-93.
114. Kosec G, Alvarez VE, Aguero F, Sánchez D, Dolinar M, Turk B, et al. Metacaspases of Trypanosoma cruzi: possible candidates for programmed cell death mediators. Mol Biochem Parasitol 2006; 145(1): 18-28.
115. Burleigh BA, Andrews N. A 120-kDa alkaline peptidase from Trypanosoma cruzi is involved in the generation of a novel Ca2+-signaling factor for mammalian cells. J Biol Chem 1995; 270(10): 5172-80.
116. 2+ signaling in mammalian cells. J Cell Biol 1997; 136(3): 609-20
117. Santana JM, Grellier P, Schrevel J, Teixeira AR. A Trypanosoma cruzi-secreted 80 kDa proteinase with specificity for human collagen types I and IV. Biochem J 1997; 325(1): 129-37.
118. Vendeville S, Bourel L, Davioud-Charvet E, Grellier P, Deprez B, Sergheraert C. Automated parallel synthesis of a tetrahydroisoqui-nolin-based library: Potential prolyl endopeptidase inhibitors. Bioorg Med Chem Lett 1999; 9: 437-42.
119. Joyeau R, Maoulida C, Guillet C, Frappier F, Teixeira AR, Schrevel J, et al. Synthesis and activity of pyrrolidinyl- and thia-zolinidyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oli-gopeptidase from T. cruzi. Eur J Med Chem 1999; 35: 257-66.
120. Grellier P, Vendeville S, Joyeau R, Bastos IMD, Drobecq H, Frappier F, et al. Trypanosoma cruzi prolyl oligopeptidase Tc80 is involved in nonphagocytic mammalian cell invasion by trypomas-tigotes. J Biol Chem 2001; 276: 47078-86.
121. Silva-Lopez RE, Morgado-Díaz JA, dos Santos PT, Giovanni-De-Simone S. Purification and subcellular localization of a secreted 75 kDa Trypanosoma cruzi serine oligopeptidase. Acta Trop 2008; 107(2): 159-67.
122. Morty RE, Shih AY, Fulop V, Andrews NW. Identification of the reactive cysteine residues in oligopeptidase B from Trypanosoma brucei. FEBS Lett 2005; 579(10): 2191-6.
123. Bal G, Van der Veken P, Antonov D, Lambeir AM, Grellier P, Croft SL, et al. Prolylisoxazoles: Potent inhibitors of prolyloli-gopeptidase with anti-trypanosomal activity. Bioorg Med Chem Lett 2003; 13(17): 2875-8.
124. Bastos IM, Grellier P, Martins NF, Cadavid-Restrepo G, de Souza-Ault MR, Augustyns K, et al. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem J 2005; 388(1): 29-38.
125. Cuevas IC, Cazzulo JJ, Sanchez D. gp63 homologues in Trypano-soma cruzi: Surface antigens with metalloprotease activity and a possible role in host cell infection. Infect Immun 2003; 71(10): 5739-49.
126. Pinho RT, Beltramini LM, Alves CR, De-Simone SG. Trypano-soma cruzi: Isolation and characterization of aspartyl proteases. Exp Parasitol 2009; 122(2): 128-33.
127. Paugam A, Bulteau AL, Dupuoy-Camet J, Creuzet C, Friguet B. Characterization and role of protozoan parasite proteasomes. Trends Parasitol 2003; 19(2): 55-9.
128. Gonzalez J, Ramalho-Pinto FJ, Frevert U, Ghiso J, Tomlinson S, Scharfstein J, et al. Proteasome activity is required for the stage-specific transformation of a protozoan parasite. J Exp Med 1996; 184(5): 1909-18.
129. de Diego JL, Katz JM, Marshall P, Gutiérrez B, Manning JE, Nussenzweig V, et al. The ubiquitin-proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. Biochemistry 2001; 40(4): 1053-62.
130. Cardoso J, Soares MJ, Menna-Barreto RF, Bloas RL, Sotomaior V, Goldenberg S, et al. Inhibition of proteasome activity blocks Try-panosoma cruzi growth and metacyclogenesis. Parasitol Res 2008; 103(4): 941-51.
131. Palladino, M., Neuteboom, S.T.C., Macherla, V.R.R., Potts, B.C. Methods of using [3.2.0]heterocyclic compounds and analogs thereof. WO2005002572 (2005).
132. Steverding D, Spackman RW, Royle HJ, Glenn RJ. Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors. Parasitol Res 2005; 95(1): 73-6.
133. Schaller H. The role of sterols in plant growth and development. Prog Lipid Res 2003; 42(3): 163-75.
134. Quinones W, Urbina JA, Dubourdieu M, Luis Concepcion J. The glycosome membrane of Trypanosoma cruzi epimastigotes: Protein and lipid composition. Exp Parasitol 2004; 106: 135-49.
135. Urbina JA. Chemotherapy of Chagas' disease: The how and the why. J Mol Med 1999; 77(3): 332-8.
136. Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Des 2002; 8(4): 287-95.
137. Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49(11): 1685-7.
138. Urbina JA, Payares G, Molina JT, Sanoja C, Liendo A, Lazardi K, et al. Cure of short-and long-term experimental Chagas disease using D0870. Science 1996; 273: 969-71.
139. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, et al. Antiproliferative effects and mechanism of action of SCH56592 against Trypanosoma cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1998; 42: 1771-7.
140. Urbina JA, Lira R, Visbal G, Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypa-num) cruzi. Antimicrob Agents Chemother 2000; 44(9): 2498-502.
141. Urbina JA, Payares C, Sanoja C, Molina J, Lira R, Brener Z, et al. Parasitological cure of acute and chronic experimental Chagas disease using a long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003; 21: 39-48.
142. Lepesheva GI, Waterman, MR. CYP51-the omnipotent P450. Mol Cell Endocrinol 2004; 215: 165-70.
143. Lepesheva GI, Zaitzeva NG, Nes WD, Zhou W, Arase M, Liu J, et al. CYP51 from Trypanosoma cruzi: A phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 2006; 281(6): 3577-85.
144. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cyto-chrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta 2007; 1770 (3): 467-77.
145. Hanskins EG, Gillespie JR, Aikenhead K, Buckner FS. Upregula-tion of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol 2005; 144(1): 68-75.
146. Chen CK, Leung SS, Guilbert C, Jacobson MP, McKerrow JH, Podust LM. Structural characterization of CYP51 from Trypano-soma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. Plos Negl. Trop dis. 2010b; 4(4): e651.
147. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, et al. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 2010; 285(33): 25582-90.
148. Apt W, Aguilera X, Arribada A, Miranda C, Sanchez G, S Zulantay I, et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am J Trop Med Hyg 1998; 59: 133-8.
149. Guedes PMM, Urbina JA, de Lana M, Afonso LC, Veloso VM, Tafuri WL, et al. Activity of the new derivative Albuconazole against Trypanosoma cruzi in dog hosts. Antimicrob Agents Che-moter 2004; 48(11): 4286-92.
150. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21(1): 27-38.
151. Buckner FS, Wilson AJ, White TC, Van Vooris WC. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother 1998; 42(12): 3245-50.
152. Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, et al. A class of sterol 14-demethylase inhibitors as anti- Trypanosoma cruzi agents. Proc Natl Acad Sci USA 2003; 100(25): 15149-53.
153. Hucke O, Gelb MH, Verlinde CL, Buckner FS. The protein farne-syltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005; 48(17): 5415-8.
154. Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, Waterman MR. CYP51: A major drug target in the cytochrome P450 superfamily. Lipids 2008; 43(12): 1117-25.
155. Benaim G, Sanders JM, Garcia-Marchan Y, Colina C, Lira R, Caldera AR, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006; 49(3): 892-9.
156. Paniz-Mondolfi AE, Pérez-Alvarez AM, Lanza G, Márquez E, Concepción JL. Amiodarone and itraconazole: A rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy 2009; 55(4): 228-33.
157. Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 2008; 625: 61-80.
158. Suryadevara PK, Olepu S, Lockman JW, Ohkanda J, Karimi M, Verlinde CL, et al. Structurally simple inhibitors of lanosterol 14alphademethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem 2009; 52(12): 3703-15.
159. Urbina J. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1): 311-8.
160. Jouvert BM, Buckner FS, Matsuda SP. Trypanosome and animal lanosterol synthases use different catalytic motifs. Org Lett 2001; 14: 1957-60.
161. Kraus JM, Tatipaka HB, Mc Guffin SA, Chennamaneni NK, Karimi M, Arif J, et al. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem 2010; 53(10): 3887-98.
162. Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SSF, Jacob-son MP, et al. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Che-mother 2010; 54(6): 2480-8.
163. Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, et al. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J Med Chem 2009; 52(9): 2846-53.
164. Rose IC, Sharpe BA, Lee RC, Griffin JH, Capobianco JO, Zakula D, et al. Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. Bioorg Med Chem 1996; 4: 97-103.
165. Buckner FS, Griffin JH, Wilson AJ, Van Voorhis WC. Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother 2001; 45(4): 1210-5.
166. Oliaro-Bosso S, Ceruti M, Balliano G, Milla P, Rocco F, Viola F. Analogs of squalene and oxidosqualene inhibit oxidosqualene cy-clase of Trypanosoma cruzi expressed in Saccharomyces cere-visiae. Lipids 2005; 40(12): 1257-62.
167. Prestwich, G.D., Buckner, F.S., Hinshaw, J.C. Methods related to metabolism of parasites and mycobacteria. WO200076316A2/A3 (2000).
168. Balliano G, Dehmlow H, Oliaro-Bosso S, Scaldaferri M, Taramino S, Viola F, et al. Oxidosqualene cyclase from Saccharomyces cere-visiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: A model for the development of novel antiparasitic agents. Bioorg Med Chem Lett 2009; 19(3): 718-23.
169. Abe I, Prestwich GD. In Cane DE Ed, Comprehensive natural products chemistry. New York, Elsevier 1999; 2(10): 267-98.
170. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997; 114: 91-9.
171. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 2002; 125(1-2): 35-45.
172. Urbina JA, Concepcion JL, Caldera A, Payares G, Sanoja C, Otomo T, et al. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004; 48(7): 2379-87.
173. Szajnman SH, Yan W, Bayley BN, Docampo R, Elhalem E, Rodriguez JB. Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J Med Chem 2000; 43(9): 1826-40.
174. Elhalem E, Bailey BN, Docampo R, Ujvary I, Szajnman SH, Rodriguez JB. Design, synthesis, and biological evaluation of ary-loxyethyl thiocyanate derivatives against Trypanosoma cruzi. J Med Chem 2002; 45(18): 3984-99.
175. Urbina JA, Concepcion JL, Montalvetti A, Rodriguez JB, Docampo R. Mechanism of action of 4- phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Cha-gas'disease. Antimibrob Agents Chemoter 2003; 47(6): 2047-50
176. Braga MV, Urbina JA, de Souza W. Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 2004; 24(1): 72-8.
177. Hiyoshi H, Yanagimachi M, Ito M, Yasuda N, Okada T, Ikuta H, Shinmyo D, et al. Squalene synthase inhibitors suppress triglyc-eride biosy.nthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003; 44(1): 128-35.
178. Lorente OS, Gomez R, Jimenez C, Cammerer S, Yardley V, de Luca-Fradley K, et al. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem 2005; 13(10): 3519-29.
179. Lorente OS, Jimenez CJ, Gros L, Yardley V, de Luca-Fradley K, Croft SL, et al. Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorg Med Chem 2005; 13(18): 5435-43.
180. Urbina JA, Lazardi K, Marchan E, Visbal G, Aguirre T, Piras MM, et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma cruzi: In vitro and in vivo studies. Antimicrob Agents Chemoter 1993; 37(3): 580-91.
181. Yardley V, Crof SL. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg 1999; 61(2): 193-7.
182. Hamilton, A.D., Van Vooris, W.C., Yokoyama, K., Buckner, F.S., Ohkanda, J., Gelb, M. Compounds and methods for the inhibition of Trypanosoma Cruzi. WO2003006012 (2003).
183. Lockman, J., Hamilton, A.D., Gelb, M., Buckner, F.S., Ohkanda, J., Yokoyama, K., Van Vooris, W.C. Compounds and methods for the inhibition of Trypanosoma cruzi. CA2453396 (2003).
184. Hamilton, A.D., Van Vooris, W.C., Yokoyama, K., Buckner, F.S., Ohkanda, J., Gelb, M., Lockman J. Compounds and methods for the inhibition of Trypanosoma cruzi. BR0211098 (2004).
185. Ferella M, Li ZH, Andersson B, Docampo R. Farnesyl diphosphate synthase localizes to the cytoplasm of Trypanosoma cruzi and T. brucei. Exp Parasitol 2008; 119(2): 308-12.
186. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. Bisphosphonates are potent inhibitors of Trypano-soma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001; 276(36): 33930-7.
187. Martin MB, Grimley JS, Lewis JC, Heath HT, Bailey BN, Kendrick H, et al. Bisphosphonates inhibit the growth of Trypano-soma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001; 44(6): 909-16.
188. Garzoni LR, Caldera A, Meirelles M de N, de Castro SL, Docampo R, Meints GA, et al. Selective in vitro effects of the farnesyl pyro-phosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents 2004; 23(3): 273-85.
189. Garzoni LR, Waghabi MC, Baptista MM, de Castro SL, Meirelles M de N, Britto CC, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004; 23(3): 286-90.
190. Szajnman SH, Ravaschino EL, Docampo R, Rodriguez JB. Synthesis and biological evaluation of 1- amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 2005; 15(21): 4685-90.
191. Szajnman SH, García Liñares GE, Li ZH, Jiang C, Galizzi M, Bontempi EJ, et al. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-biphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate syn-thase. Bioorg Med Chem 2008; 16: 3283-90.
192. Docampo R, Moreno SN. Bisphosphonates as chemotherapeutic agents against Trypanosomatid and apicomplexan parasites. Curr Drug Targets Infect Disord 2001; 1(1): 51-61.
193. Gabelli SB, McLellan JS, Montalvetti A, Oldfield E, Docampo R, Amzel LM. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: Implications for drug design. Proteins 2006; 62(1): 80-8.
194. Sigman L, Sanchez VM, Turjansky AG. Characterization of the farnesyl pyrophosphate synthase of Trypanosoma cruzi by homol-ogy modeling and molecular dynamics. J Mol Graph Model 2006; 25 (3): 345-52.
195. Yokoyama K, Trobridge P, Buckner FS, Scholten J, Stuart KD, Van Voorhis WC, et al. The effects of protein farnesyltransferase inhibitors on Trypanosomatids: Inhibition of protein farnesylation and cell growth. Mol Biochem Parasitol 1998; 94(1): 87-97.
196. Gelb MH, Van Voohris WC, Buckner FS, Yokoyama K, Eastman R, Carpenter EP, et al. Protein farnesyl and N-myristoyl trans-ferases: Piggy-back medicinal chemistry targets for the development of anti-Trypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 2003; 126(2): 155-63.
197. Karp JE. Farnesyl transferase inhibition in hematologic malignancies. J Natl Comp Cancer Netw 2005; 3(1): 37-40.
198. Esteva MI, Kettler K, Maidana C, Fichera L, Ruiz AM, Bontempi EJ, et al. Benzophenone-based farnesyl transferase inhibitors with high activity against Trypanosoma cruzi. J Med Chem 2005; 48(23): 7186-91.
199. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, Buckner FS. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 2009; 52(6): 1639-47.
200. Field, M.C., Ali, B.R.S. Manumycin derivatives for treating parasitic disorders. WO200105384 (2001).
201. Windsor, W.T., Weber, P.C., Stricland, C., Syto, R., Girijavallab-han, V.M., Kaminski, J.J., Guo, Z. Treatment of Trypanosoma brucei with farnesyl protein transferase inhibitors. US2003134846 (2003).
202. Yokoyama K, Gillespie JR, Van Voorhis WC, Buckner FS, Gelb MH. Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol Biochem Parasitol 2008; 157(1): 32-43.
203. Sandes JM, Borges AR, Junior CG, Silva FPL, Carvalho GAU, Rocha GB, et al. 3-Hydroxy-2-methylene-3-(4 nitrophenylpro-panenitrile): A new highly active compound against epimastigote and trypomastigote form of Trypanosoma cruzi. Bioorg Chem 2010; 38(5):190-5.
204. Krauth-Siegel RL, Inhoff O. Parasite-specific trypanothione reduc-tase as a drug target molecule. Parasitol Res 2003; 90(2): 77-85.
205. Faundez M, Pino L, Letelier P, Ortiz C, López R, Seguel C, et al. Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob Agents Che-mother 2005; 49: 126-30.
206. Krauth-Siegel RL, Bauer H, Schirmar RH. Dithiol proteins as guardians of the intracellular redox milieu in parasites: Old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 2005; 44(5): 690-715.
207. Augustins K, Amssoms K, Yamani A, Rajan PK, Haemers A: Trypanothione as a target in the design of anti-trypanosomal and antiLeishmanial agents. Curr Pharm Des 2001; 7(12): 1117-41.
208. Stoppani AO. The chemotherapy of Chagas disease. Medicina (Bs As) 1999; 59(2): 147-65.
209. Henderson GB, Ulrich P, Fairlamb AH, Rosenberg I, Pereira M, Sela M, et al. Subversive substrates for the enzyme trypanothione disulfide reductase: Alternative approach to chemotherapy of Cha-gas disease. Proc Natl Acad Sci USA 1988; 85(15): 5374-8.
210. Salmon Chemin L, Buisine E, Yardley V, Kohler S, Debreu MA, Landri V, et al. 2- and 3-substituted 1, 4-naphthoquinone derivatives as ubversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: Synthesis and correlation between redox cycling activities and in vitro cytotoxic-ity. J Med Chem 2001; 44(4): 548-65.
211. Blumenstiel K, Schoeneck R, Yardley V, Croft SL, Krauth-Siegel RL. Nitrofuran drugs as common subversive substrates of Trypano-soma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem Pharmacol 1999; 58(11): 1791-9.
212. Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO. The chemotherapy of Chagas' disease: an overview. Mini Rev Med Chem 2005; 5(5): 499-519.
213. Santos AF, Ferraz PA, de Abreu FC, Chiari E, Goulart MO, Sant'Ana AE. Molluscicidal and trypanocidal activities of lapachol derivatives. Planta Med 2001; 67(1): 92-3.
214. De Moura KCG, Emery FS, Neves-Pinto C, Pinto MCR, Dantas AP, Salomão K, et al. Synthesis and trypanocidal activity of naph-thoquinones isolated from Tabebuia and heterocyclic derivatives: A review from an interdisciplinary study. J Braz Chem Soc 2001; 12: 325-38.
215. Cuellar MA, Salas C, Cortes MJ, Morello A, Diego Maya J, Preite MD. Synthesis and in vitro trypanocide activity of several poly-cyclic drimane-quinone derivatives. Bioorg Med Chem 2003; 11(12): 2489-97.
216. De Moura KC, Salomao K, Menna-Barreto RF, Emery FS, Pinto Mdo C, Pinto AV, et al. Studies on the trypanocidal activity of semisynthetic pyran [b-4, 3]naphtho [1,2-d]imidazoles from betha-lapachone. Eur J Med Chem 2004; 39(7): 639-45.
217. Jorqueira A, Goubea RM, Ferreira VF, de Souza MC, Zuma AA, Cavalcanti DF, et al. Oxyrane derivative of alpha-lapachone is potent growth inhibitor of Trypanosoma cruzi epimastigote forms. Pa-rasitol Res 2006; 99(4): 429-33.
218. Silva RS, Costa EM, Trindade UL, Teixeira DV, Pinto MCFR, Santos GL, et al. Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi. Eur J Med Chem 2006; 41(4): 526-30.
219. Buchholz K, Comini MA, Wissenbach D, Schirmer RH, Krauth-Siegel RL, Gromer S. Cytotoxic interactions of methylene blue with Trypanosomatid-specific disulfide reductases and their dithiol products. Mol Biochem Parasitol 2008; 160(1): 65-9.
220. Stump B, Kaiser M, Brun R, Krauth-Siegel RL, Diederich F. Betraying the parasite's redox system: Diaryl sulfide-based inhibitors of trypanothione reductase: Subversive substrates and anti-trypanosomal properties. Chem Med Chem 2007; 2(12): 1708-12.
221. Austin SE, Khan MO, Douglas KT. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-Leishmanial drug leads. Drug Des Discov 1999; 16(1): 5-23.
222. Gallwitz H, Bonse S, Martinez-Cruz A, Schichting I, Schumacher K, Krauth-Siegel RL. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi try-panothione reductase: crystallographic, kinetic, and spectroscopic studies. J Med Chem 1999; 42(3): 364-72.
223. Farrell NP, Williamson J, McLaren DJ. Trypanocidal and antitu-mour activity of platinum-metal and platinum-metal-drug dual-function complexes. Biochem Pharmacol 1984; 33(7): 961-71.
224. Bonse S, Richards JM, Ross SA, Lowe G, Krauth-Siegel RL. (2, 2': 6', 2-Terpyridine) platinum (II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J Med Chem 2000; 43(25): 4812-21.
225. Sanchez-Delgado RA, Lazardi K, Rincon L, Urbina JA. Toward a novel metal-based chemotherapy against tropical diseases. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2 (clotrimazole)2. J Med Chem 1993; 36(14): 2041-3.
226. Sanchez-Delgado RA, Anzellotti A. Metal complexes as che-motherapeutic agents against tropical diseases: Trypanosomiasis, malaria and Leishmaniasis. Mini Rev Med Chem 2004; 4(1): 23-30.
227. Lowe, G. Platinum (ii) compounds. WO200050431 (2000).
228. Lee B, Bauer H, Melchers J, Ruppert T, Rattray L, Yardley V, et al. Irreversible inactivation of trypanothione reductase by un-saturated Mannich bases: A divinyl ketone as key intermediate. J Med Chem 2005; 48(23): 7400-10.
229. Otelo L, Vieites M, Boiani L, Denicola A, Rigol C, Opazo L, et al. Novel Trypanosomal agents based on PalladiumNitro-furylthiosemicarbazone Complexes: DNA and redox Metabolism as potential therapeutic targets. J Med Chem 2006; 49(11): 3322-31.
230. Gutierrez-Correa J, Fairlamb AH, Stoppani AO. Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic Res 2001; 34(4): 363-78.
231. Rivarola HW, Paglini Oliva P. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr Drug Targets Cardio-vasc Haematol Disord 2002; 2(1): 43-52.
232. Rivarola HW, Bustamante JM, Lo Presti S, Fernández AR, Enders JE, Gea S, et al. Trypanosoma cruzi: Chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp Parasitol 2005; 111(2): 80-6.
233. Jacoby EM, Schlichting I, Lantwin CB, Kabsch W, Krauth-Siegel RL. Crystal structure of the Trypanosoma cruzi trypanothione re-ductase-mepacrine complex. Proteins 1996; 24(1): 73-80.
234. Girault S, Davioud-Charvet E, Salmon L, Berecibar A, Debreu MA, Sergheraert C. Structure-activity relationships in 2-aminodiphenylsulfides against trypanothione reductase from Try-panosoma cruzi. Bioorg Med Chem Lett 1998; 8(10): 1175-80.
235. Girault S, Davioud-Charvet TE, Maes L, Dubremetz JF, Debreu MA, Landry V, et al. Potent and specific inhibitors of trypan-othione reductase from Trypanosoma cruzi: Bis(2-amino-diphenylsulfides) for fluorescent labeling studies. Bioorg Med Chem 2001; 9(4): 837-46.
236. Bonnet B, Soullez D, Davioud-Charvet E, Landry V, Horvath D, Sergheraert C. New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase. Bioorg Med Chem 1997; 5(7): 1249-56.
237. Li Z, Fennie MW, Ganem B, Hancock MT, Lija MK, Rattendi D, et al. Polyamines with N-(3-phenylpropyl) substituents are effective competitive inhibitors of trypanothione reductase and trypano-cidal agents. Bioorg Med Chem Lett 2001; 11(2): 251-4.
238. Flohe L, Hecht HJ, Steinert T. Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radic Biol Med 1999; 27(9-10): 966-84.
239. Fournet A, de Arias RA, Ferreira ME, Nakayama H, de Ortiz ST, Schinini A, et al. Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model. Int J Antimi-crob Agents 2000; 13(3): 189-95.
240. Khan MO, Austin SE, Chan C, Yin H, Marks D, Vaghjiani SN, et al. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. J Med Chem 2000; 43(16): 3148-56.
241. Parveen S, Khan MO, Austin SE, Croft SL, Yardley V, Rock P, et al. Anti-Trypanosomal, anti-Leishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sul-fide. J Med Chem 2005; 48(25): 8087-97.
242. Aguirre G, Cabrera E, Cerecetto H, Di Maio R, González M, Seoane G, et al. Design, synthesis and biological evaluation of new potent 5- nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. Eur J Med Chem 2004; 39(5): 421-31.
243. Aguirre G, Boiani M, Cabrera E, Cerecetto H, Di Maio R, González M, et al. New potent 5-nitrofuryl derivatives as inhibitors of Trypanosoma cruzi growth. 3D-QSAR (CoMFA) studies. Eur J Med Chem 2006; 41(4): 457-66.
244. Meiering S, Inhoff O, Mies J, Vincek A, Garcia G, Kramer B, et al. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J Med Chem 2005; 48(15): 4793-802.
245. Galarreta BC, Sifuentes R, Carrillo AK, Sanchez L, del Amado MR, Maruenda H. The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem 2008; 16(14): 6689-95.
246. Czechowicz JA, Wilhelm AK, Spalding MD, Larson AM, Engel LK, Alberg DG. The synthesis and inhibitory activity of dethiotry-panothione and analogues against trypanothione reductase. J Org Chem 2007; 72(10): 3689-93.
247. Wilkinson SR, Obado SO, Mauricio IL, Kelly JM. Trypanosoma cruzi expresses a plant-like ascorbate dependent hemoperoxidase localized to the endoplasmic reticulum. Proc Natl Acad Sci USA 2002; 99(21): 13453-8.
248. Cota BB, Rosa LH, Fagundes EM, Martins-Filho OA, Correa-Oliveira R, Romanha AJ, et al. A potent trypanocidal component from the fungus Lentinus strigosus inhibits trypanothione reductase and modulates PBMC proliferation. Mem Inst Oswaldo Cruz 2008; 103(3): 263-70.
249. Cota BB, Rosa LH, Caligiorne RB, Rabello AL, Almeida Alves TM, Rosa CA, et al. Altenusin, a biphenyl isolated from the endo-phytic fungus Alternaria sp., inhibits trypanothione reductase from Trypanosoma cruzi. FEMS Microbiol Lett 2008; 285(2):177-82.
250. Rosa LH, Machado KM, Rabello AL, Souza-Fagundes EM, Correa-Oliveira R, Rosa CA, et al. Cytotoxic, immunosuppressive, trypanocidal and antileishmanial activities of Basidiomycota fungi present in Atlantic Rainforest in Brazil. Antonie Van Leeuwenhoek 2009; 95(3): 227-37.
251. Cavalli A, Lizzi F, Bongarzone S, Brun R, Luise Krauth-Siegel R, Bolognesi ML. Privileged structure guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. Bioorg Med Chem Lett 2009; 19(11): 3031-5.
252. Porcal W, Hernández P, Boiani L, Boiani M, Ferreira A, Chidichimo A, et al. New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorg Med Chem 2008; 16(14): 6995-04.
253. Eberle C, Lauber BS, Fankhauser D, Kaiser M, Brun R, Krauth-Siegel RL, et al. Improved inhibitors of Trypanothione Reductase by combination of motifs: Synthesis, inhibitory potency, binding mode, and antiprotozoal activities. Chem Med Chem 2010; 6(2): 292-301.
254. McKie JH, Garforth J, Jaouhari R, Chan C, Yin H, Besheya T, et al. Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: Potential rational drug design lead frameworks Amino. Acids 2001; 20(2): 145-53.
255. Da Rocha Pita SS, Cirino JJ, de Alencastro RB, Castro HC, Rodriguez CR, Albuquerque MG. Molecular docking of a series of pep-tidomimetics in the trypanothione binding site of T. cruzi trypan-othione reductase. J Mol Graph Model 2009; 28(4): 330-5.
256. Garavaglia PA, Cannata JJ, Ruiz AM, Maugeri D, Duran R, Galleano M, et al. Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxido-reductase activity. Mol Biochem Parasitol 2010; 173(2):132-41.
257. Olin-Sandoval V, Moreno Sanchez R, Saavedra E. Targeting trypanothione metabolism in trypanosomatid human parasites. Curr Drug targets 2010; 11(12): 1614-30.
258. Marquez VE, Arias DG, Piattoti CV, Rovello C, Iglesias AA, Guerrero AS. Cloning, expression, and characterization of a dithiol glutaredoxin from Trypanosoma cruzi. Antioxid Redox Signal 2010; 12(6): 787-92.
259. Ravaschino EL, Docampo R, Rodriguez JB. Design, synthesis, and biological evaluation of phosphinopeptides against Trypanosoma cruzi targeting trypanothione biosynthesis. J Med Chem 2006; 49(1): 426-35.
260. Oza SL, Chen S, Wyllie S, Coward JK, Fairlamb AH. ATP-dependent ligases in trypanothione biosynthesis-kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. FEBS J 2008; 275(21): 5408-21.
261. Greig N, Wyllie S, Vickers TJ, Fairlamb AH. Trypanothione-dependent glyoxalase I in Trypanosoma cruzi. Biochem J 2006; 400(2): 217-23.
262. Greig N, Wyllie S, Patterson S, Fairlamb AH. A comparative study of methylglyoxal metabolism in Trypanosomatids. FEBS J 2009; 276(2): 376-86.
263. Flohe, L., Koenig, K., Menge, U. Glutathionylspermidine syn-thetase and processes for recovery and use thereof. US6291217 (2001).
264. Wyllie S, Fairlamb AH. Methylglyoxal metabolism in trypano-somes and leishmania. Semin Cell Dev Biol. 2011, in press.
265. Engel JC, de Cazzulo FBM, Stoppani AO, Cannata JJ, Cazzulo JJ. Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimas-tigotes. Mol Biochem Parasitol 1987; 26 (1-2): 1-10.
266. Souza DH, Garratt RC, Araújo AP, Guimarães BG, Jesus WD, Michels PA, et al. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: Structure, catalytic mechanism and targeted inhibitor design. FEBS Lett 1998; 424(3):131-5.
267. Aronov AM, Suresh S, Buckner FS, Van Voorhis WC, Verlinde CL, Opperdoes FR, et al. Structure-based design of submicromolar, biologically active inhibitors of Trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci USA 1999; 96(8): 4273-8.
268. Bressi JC, Verlinde CL, Aronov AM, Shaw ML, Shin SS, Nguyen LN, et al. Adenosine analogues as selective inhibitors of glyceral-dehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem 2001; 44(13): 2080-93.
269. Tomazela DM, Pupo MT, Passador EA, da Silva MF, Vieira PC, Fernandes JB, et al. Pyrano chalcones and a flavone from Neorapu-tia magnifica and their Trypanosoma cruzi glycosomal glyceral-dehyde-3-phosphate dehydrogenase-inhibitory activities. Phyto-chemistry 2000; 55(6): 643-51.
270. Ladame S, Castilho MS, Silva CH, Denier C, Hannaert V, Périé J, et al. Crystal structure of Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase complexed with an analogue of 1, 3-bisphospho-d-glyceric acid. Eur J Biochem 2003; 270(22): 4574-86.
271. de Marchi AA, Castilho MS, Nascimento PG, Archanjo FC, del Ponte G, Oliva G, et al. New 3-Piperonylcoumarins as inhibitors of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAP-DH) from Trypanosoma cruzi. Bioorg Med Chem 2004; 12(18): 4823-33.
272. da Silva R, Saraiva J, de Albuquerque S, Curti C, Donate PM, Bianco TN, et al. Trypanocidal structure-activity relationship for cis- and trans-methylpluviatolide. Phytochemistry 2008; 69(9): 1890-4.
273. Ladame S, Fauré R, Denier C, Lakhdar-Ghazal F, Willson M. Selective inhibition of Trypanosoma cruzi GAPDH by bi-substrate analogues. Org Biomol Chem 2005; 3(11): 2070-2.
274. Freitas RF, Prokopczyk IM, Zottis A, Oliva G, Andricopulo AD, Trevisan MT, et al. Discovery of novel Trypanosoma cruzi glycer-aldehyde-3- phosphate dehydrogenase inhibitors. Bioorg Med Chem 2009; 17(6): 2476-82.
275. Pereira JM, Severino RP, Vieira PC, Fernandes JB, da Silva MF, Zottis A, et al. Anacardic acid derivatives as inhibitors of glyceral-dehyde-3-phosphate dehydrogenase from Trypanosoma cruzi phosphate dehydrogenase inhibitors. Bioorg Med Chem 2008; 16(19): 8889-95.
276. Silva JJ, Guedes PM, Zottis A, Balliano TL, Nascimento Silva FO, França Lopes LG, et al, Novel ruthenium complexes as potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity. Br J Pharmacol 2010; 160(2): 260-9.
277. Hudock MP, Sanz-Rodríguez CE, Song Y, Chan JM, Zhang Y, Odeh S, et al. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 2006; 49(1): 215-23.
278. Cáceres AJ, Quiñones W, Gualdrón M, Cordeiro A, Avilán L, Michels PA, et al. Molecular and biochemical characterization of novel glucokinases from Trypanosoma cruzi and Leishmania sp. Mol Biochem Parasitol 2007; 156 (2): 235-45.
279. Cordeiro AT, Cáceres AJ, Vertommen D, Concepción JL, Michels PA, Versées W. The crystal structure of Trypanosoma cruzi glu-cokinase reveals features determining oligomerization and anomer specificity of hexose-phosphorylating enzymes. J Mol Biol 2007; 372(5): 1215-26.
280. Sanz-Rodríguez CE, Concepción JL, Pekerar S, Oldfield E, Urbina JA. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: Kinetic and metabolic studies. J Biol Chem 2007; 282(17): 12377-87.
281. Chelesky J, Freites RF, Wiggers HJ, Rocha JR, de Araujo AP, Montanari CA. Expression, purification and kinetic characterization of His-tagged glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi. Protein Expr Purif 2011; 76(2): 190-6.
282. Gupta S, Cordeiro AT, Michels PA. Glucose-6-phosphate dehydro-genase is the target for the trypanocidal action of human steroids. Mol Biochem Parasitol 2011; 176 (2): 112-5.
283. Alvarez G, Aguirre-López B, Varela J, Cabrera M, Merlino A, López GV, et al. Massive screening yields novel and selective Try-panosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. Eur J Med Chem 2010; 45(12): 5767-72.
284. Maugeri DA, Cazzulo JJ. The pentose phosphate pathway in Try-panosoma cruzi. FEMS Microbiol Lett 2004; 234(1): 117-23.
285. Igoillo-Esteve MI, Cazzulo JJ. The glucose-6-phosphate dehydro-genase from Trypanosoma cruzi: Its role in the defense of the parasite against oxidative stress. Mol Biochem Parasitol 2006; 149(2): 170-81.
286. Igoillo-Esteve M, Maugeri D, Stern AL, Beluardi P, Cazzulo JJ. The pentose phosphate pathway in Trypanosoma cruzi: A potential target for the chemotherapy of Chagas disease. Acad Bras Cienc 2007; 79(4): 649-63.
287. Stern AL, Burgos E, Salmon L, Cazzulo JJ. Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: Kinetic properties and site-directed mutagenesis reveal information about the reaction mechanism. Biochem J 2007; 401(1): 279-85.
288. Mielniczki-Pereira AA, Chiavegatto CM, López JA, Colli W, Alves MJ, Gadelha FR. Trypanosoma cruzi strains, Tulahuen 2 and Y, besides the difference in resistance to oxidative stress, display differential glucose-6-phosphate and 6-phosphogluconate dehydro-genases activities. Acta Trop 2007; 101(1): 54-60.
289. Cordeiro AT, Thiemann OH. 16-Bromoepiandrosterone, an activator of the mammalian immune system, inhibits glucose 6-phosphate dehydrogenase from Trypanosoma cruzi and is toxic to these parasites grown in culture. Bioorg Med Chem 2010; 18(13): 4762-8.
290. Pereira CA, Alonso GD, Paveto MC, Iribarren A, Cabanas ML, Torres HN, et al. Trypanosoma cruzi arginine kinase characterization and cloning. A novel energetic pathway in protozoan parasites. J Biol Chem 2000; 275(2): 1495-501.
291. Pereira CA, Alonso GD, Ivaldi S, Silber A, Alves MJ, Bouvier LA, et al. Arginine metabolism in Trypanosoma cruzi is coupled to parasite stage and replication. FEBS Lett 2002; 526(1-3): 111-4.
292. Miranda MR, Canepa GE, Bouvier LA, Pereira CA. Trypanosoma cruzi: Oxidative stress induces arginine kinase expression. Exp Parasitol 2006; 114(4): 341-4.
293. Fernandez P, Haouz A, Pereira CA, Aguilar C, Alzari PM. The crystal structure of Trypanosoma cruzi arginine kinase. Proteins 2007; 69(1): 209-12.
294. Miranda MR, Bouvier LA, Canepa GE, Pereira CA. Subcellular localization of Trypanosoma cruzi arginine kinase. Parasitology 2009; 27: 1-7.
295. Paveto C, Güida MC, Esteva MI, Martino V, Coussio J, Flawiá MM, et al. Anti-Trypanosoma cruzi activity of green tea (Camellia sinensis) catechins. Antimicrob Agents Chemother 2004; 48(1): 69-74.
296. Silber AM, Colli W, Ulrich H, Alves MJ, Pereira CA. Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease. Curr Drug Targets Infect Disord 2005; 5(1): 53-64.
297. Chamond N, Grégoire C, Coatnoan N, Rougeot C, Freitas-Junior LH, da Silveira JF, et al. Biochemical characterization of praline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures. J Biol Chem 2003; 278(18): 15484-94.
298. Chamond N, Goytia M, Coatnoan N, Barale JC, Cosson A, Degrave WM, et al. Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity. Mol Microbiol 2005; 58(1): 46-60.
299. Buschiazzo A, Goytia M, Schaeffer F, Degrave W, Shepard W, Gregoire C, et al. Crystal structure, catalytic mechanism, and mito-genic properties of Trypanosoma cruzi proline racemase. Proc Natl Acad Sci USA 2006; 103(6): 1705-10.
300. Coatnoan N, Berneman A, Chamond N, Minoprio P. Proline race-mases: Insights into Trypanosoma cruzi peptides containing D-proline. Mem Inst Oswaldo Cruz 2009; 104(4): 295-300.
301. Minoprio, P., Chamond, N., Degrave, W., Berneman, A. Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase. US7262015 (2007), US7556939 (2009).
302. Minoprio, P., Alzari, P., Buscchiazzo, A., Gregoire, C., Bernenam, A., Degrave, W.M. Crystallographic structure of TcPRACA and uses therefor. US7585656 (2009).
303. Coutinho L, Ferreira MA, Cosson A, Batista MM, Batista D da G, Minoprio P, et al. Inhibition of Trypanosoma cruzi proline race-mase affects host-parasite interactions and the outcome of in vitro infection. Mem Inst Oswaldo Cruz 2009; 104 (8): 1055-62.
304. Minoprio, P., Arala Chaves, M., Fernandez de Almeida, S.I., Coutinho, A., San Martin, B.R., Rougeot, C., Degrave, W., Cosson, A. Cloning, sequencing and expression of a gene encoding an eu-karyotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens. US7732563 (2010), US7851603 (2010)
305. Naula C, Parsons M, Mottram JC. Protein kinases as drug targets in Trypanosomes and Leishmania. Biochim Biophys Acta 2005; 1754 (1-2): 151-9.
306. Bao Y, Weiss LM, Hashimoto M, Nara T, Huang H. Protein kinase A regulatory subunit interacts with P type ATPases in Trypano-soma cruzi. Am J Trop Med Hyg 2009; 80(6): 941-3.
307. Belaunzarán ML, Lammel EM, Giménez G, Wainszelbaum MJ, de Isola EL. Involvement of protein kinase C isoenzymes in Trypano-soma cruzi metacyclogenesis induced by oleic acid. Parasitol Res 2009; 105(1): 47-55.
308. Braga MV, de Souza W. Effects of protein kinase and phosphatidy-linositol-3 kinase inhibitors on growth and ultrastructure of Try-panosoma cruzi. FEMS Microbiol Lett 2006; 256(2): 209-16.
309. Saraiva VB, Wengert M, Gomes-Quintana E, Heise N, Caruso-Neves C. Na (+)-ATPase and protein kinase C are targets to 1-O-hexadecylphosphocoline (miltefosine) in Trypanosoma cruzi. Arch Biochem Biophys 2009; 481(1): 65-71.
310. Ariyanayagam MR, Fairlamb AH. Diamine auxotrophy may be a universal feature of Trypanosoma cruzi epimastigotes. Mol Bio-chem Parasitol 1997; 84(1): 111-21.
311. Majumder S, Wirth JJ, Bitonti AJ, McCann PP, Kierszenbaum F. Biochemical evidence for the presence of arginine decarboxylase activity in Trypanosoma cruzi. J Parasitol 1992; 78(2): 371-4.
312. Menezes D, Valentim C, Oliveira MF, Vannier-Santos MA. Putres-cine analogue cytotoxicity against Trypanosoma cruzi. Parasitol Res 2006; 98(2): 99-105.
313. Audette, M., Charest-Gaudrealt, R. Polyamine transport inhibitors. US6949679 (2005).
314. Carrillo C, González NS, Algranati ID. Trypanosoma cruzi as a model system to study the expression of exogenous genes coding for polyamine biosynthetic enzymes. Biochim Biophys Acta 2007; 1770(12): 1605-11.
315. Goebel T, Ulmer D, Projahn H, Kloeckner J, Heller E, Glaser M, et al. In search of novel agents for therapy of tropical diseases and human immunodeficiency virus. J Med Chem 2008; 51(2): 238-50.
316. Heby O, Persson L, Rentala M. Targeting the polyamine biosyn-thetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas' disease, and Leishmaniasis. Amino Acids 2007; 33(2): 359-66.
317. Pereira CA, Carrillo C, Miranda MR, Bouvier LA, Canepa GE. Trypanosoma cruzi: transport of essential metabolites acquired from the host. Medicina (Bs As) 2008; 68(5): 398-404.
318. Ullman B, Carter D. Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. Int J Parasitol 1997; 27(2): 203-13.
319. Nakajima-Shimada J, Hirota Y, Aoki T. Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Antimicrob Agents Chemother 1996; 40(11): 2455-8.
320. Marr JJ, Berens RL, Nelson DJ. Antitrypanosomal effect of al-lopurinol: conversion in vivo to aminopyrazolopyrimidine nucleo-tides by Trypanosoma curzi. Science 1978; 201(4360): 1018-20.
321. Avila JL, Avila A, Munoz E. Effect of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 1981; 30(4): 769-74.
322. Eakin AE, Guerra A, Focia PJ, Torres-Martinez, Craig SP. Hy-poxanthine hosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: Crystallization and inhibition studies with purine analogs. Antimicrob Agents Chemother 1997; 41(8): 1686-92.
323. Freymann DM, Wenck MA, Engel JC, Feng J, Focia PJ, Eakin AE, et al. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol 2000; 7(12): 957-68.
324. Wenck MA, Medrano FJ, Eakin AE, Craig SP. Steady-state kinetics of the hypoxanthine phosphoribosyltransferase from Trypano-soma cruzi. Biochim Biophys Acta 2004; 1700 (1): 11-18.
325. Reche P, Arrebola R, Santi DV, Pacanowska GD, Perez RLM. Expression and characterization of the Trypanosoma cruzi dihydro-folate reductase domain. Mol Biochem Parasitol 1996; 76(1-2): 175-85.
326. Gilbert IH. Inhibitors of dihydrofolate reductase in Leishmania and Trypanosomes. Biochim Biophys Acta 2002; 1587(2-3): 249-57.
327. Schormann N, Senkovich O, Walker K, Wright DL, Anderson AC, Rosowsky, et al. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function. Proteins 2008; 73(4): 889-901.
328. Senkovich O, Schormann N, Chattopadhyay D. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. Acta Crystallogr D Biol Crystallogr 2009; 65(7): 704-16.
329. Chitnumsub P, Yuvaniyama J, Chahomchuen J, Valaivan T, Yuthavon Y. Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypano-soma cruzi, the Chagas disease pathogen. Acta Crystalllogr Sect F Struct Biol Cryst Commun 2009; 65(11): 1175-8.
330. Schormann N, Velu SE, Murugesan S, Senkovich O, Walker K, Chenna BC, et al. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem 2010; 18(11): 4056-66.
331. Chowdhury SF, Guerrero RH, Brun R, Ruiz-Perez L, Pacanowska DG, Gilbert IH. Synthesis and testing of 5-benzyl-2, 4-diaminopyrimidines as potential inhibitors of Leishmanial and Try-panosomal dihydrofolate reductase. J Enzyme Inhib Med Chem 2002; 17(5): 293-302.
332. Pez D, Leal I, Zuccotto F, Boussard C, Brun R, Croft SL, et al. 2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanoso-mal dihydrofolate reductase. Bioorg Med Chem 2003; 11(22): 4693-711.
333. Khabnadidesh S, Pez D, Musso A, Brun R, Pérez LM, González-Pacanowska D, et al. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of Trypanosomal and Leishma-nial dihydrofolate reductase. Bioorg Med Chem 2005; 13(7): 2637-49.
334. Sencovich O, Bhatia V, Garg N, Chattopadhyay D. Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi. Prospect Chemotherap 2005; 49(8): 3234-8.
335. Nare B, Luba J, Hardy LW, Beverley SM. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 1997; 114 (Suppl): 101-10.
336. Schormann N, Pal B, Chattopadhyay D. Expression, purification, crystallization and preliminary crystallographic analysis of recom-binant pteridine reductase of Trypanosoma cruzi. Acta Crystallogr D Biol Crystallogr 2001; 57(11): 1671-3.
337. Senkovich O, Pal B, Schormann N, Chattopadhyay D. Trypano-soma cruzi genome encodes a pteridine reductase 2 protein. Mol Biochem Parasitol 2003; 127(1): 89-92.
338. Schormann N, Pal B, Senkovich O, Carson M, Howard A, Smith C, et al. Crystal structure of Trypanosoma cruzi pteridine reductase 2 in complex with a substrate and an inhibitor. J Struct Biol 2005; 152(1): 64-75.
339. Lowe, G. Dihydrofolate reductase inhibitors. WO0153276 (2001).
340. Lawton P. Purine analogs as antiparasitic agents Expert Opin Ther Pat 2005; 15(8): 987-94.
341. Bottaro, J.C., Schmitt, R.J., Petrie, M.A., Penwell, P.E. Nucleoside pyrophosphate and triphosphate analogs and related compounds as therapeutic agents. WO0114401 (2001).
342. Cavazzuti A, Paglietti G, Hunter WN, Gamarro F, Piras S, Loriga M, et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 2008; 105(5): 1448-53.
343. Nara T, Kamei Y, Tsubouchi A, Annoura T, Hirota K, Iizumi K, et al. Inhibitory action of marine algae extracts on the Trypano-soma cruzi dihydroorotate dehydrogenase activity and on the protozoan growth in mammalian cells. Parasitol Int 2005; 54 (1): 59-64.
344. Inaoka DK, Tashamira E, Osanai A. Expression, purification and crystallization of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with orotate. Acta Cryst Sec F Struct Biol Cryst Com-mun 2005; 61(10): 875-8.
345. Pinheiro MP, Iulek J, Nonato CM. Crystal structure of Trypano-soma cruzi dihydroorotate dehydrogenase from Y strain. Biochem Biophys Res Commun 2008; 369(3): 812-7.
346. Inaoka DK, Sakamoto K, Shimizu H, Shiba T, Kurisu G, Nara T, et al. Structures of Trypanosoma cruzi dihydroorotate dehydro-genase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction. Biochemistry 2008; 47(41): 10881-91.
347. Cheleski J, Rocha JR, Pinheiro MP, Wiggers HJ, da Silva AB, Nonato MC, et al., Novel insights for dihydroorotate dehydro-genase class 1A inhibitors discovery. Eur J Med Chem 2010; 45(12): 5899-09.
348. Berg M, van der Veken P, Goeminne A, Haemers A, Augustyns K. Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy? Curr Med Chem 2010; 17(23): 2456-81.
349. Gonzales-Perdomo M, de Castro SL, Meirelles MN, Goldenberg S. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 1990; 34(9): 1707-14.
350. Morales J, Mogi T, Mineki S, Takashima E, Mineki R, Hirawake H, et al. Novel mitochondrial complex II isolated from Trypano-soma cruzi is composed of 12 peptides including a heterodimeric Ip subunit. J Biol Chem 2009; 284(11): 7255-63.
351. Abdul-Rahman, S. Compounds with antibacterial and antiparasitic properties. US6967205 (2005).
352. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camp-tothecin, a topoisomerase I inhibitor, on Trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995; 92(9): 3726-30.
353. Stephens CE, Brun R, Salem MM, Werbovetz KA, Tanious F, Wilson FD, et al. The activity of diguanidino and 'reversed' dia-midino 2, 5- diarylfurans versus Trypanosoma cruzi and Leishma-nia donovani. Bioorg Med Chem Lett 2003; 13(12): 2065-9.
354. Werbovetz K. Diamidines as anti-Trypanosomal, anti-Leishmanial and antimalarial agents. Curr Opin Investig Drugs 2006; 7(2): 147-57.
355. Boykin, D., Tidwell, R.R., Wilson, W.D., Perfect, J.R., Stephens, C.E. Synthesis and antimicrobial activityof novel dicationic reversed amidines. WO2002057224 (2002).
356. da Silva CF, Batista MM, Batista D da G, de Souza EM, da Silva PB, de Oliveira GM, et al. In vitro and in vivo studies of the try-panocidal activity of a diarylthiophene diamidine against Trypano-soma cruzi. Antimicrob Agents Chemother 2008; 52(9): 3307-14.
357. Silva CF, Batista MM, Mota RA, de Souza EM, da Silva PB, de Oliveira GM, et al. Activity of reversed diamidines against Trypanosoma cruzi in vitro. Biochem Pharmacol 2007; 73(12): 1939-46.
358. Werbovetz, K., Bhatta Charya, G., Sackett, D., Salem, M.M. Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin. WO2003090678 (2003).
359. Benítez J, Guggeri L, Tomaz I, Arrambide G, Navarro M, Pessoa JC, et al. Design of vanadium mixed-ligand complexes as potential anti protozoa agents. J Inorg Biochem 2009; 103(4): 609-16.
360. Glass LS, Nguyen B, Goodwin KD, Dardonville C, Wilson WD, Long EC, et al. Crystal structure of a trypanocidal 4,4'-bis (imida-zolinylamino)diphenylamine bound to DNA. Biochemistry 2009; 48(25): 5943-52.
361. Stolic I, Miskovic K, Magdaleno A, Silber AM, Piantanida I, Bajic M, et al. Effect of 3,4-ethylenedioxy-extension of thiophene core on the DNA/RNA binding properties and biological activity of bis-benzimidazole amidines. Bioorg Med Chem 2009; 17(6): 2544-54.
362. Ochola DO, Prichard RK, Lubega GW. Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasi-tol 2002; 88(3): 600-04.
363. Morgan RE, Werbovetz KA. Selective lead compounds against kinetoplastid tubulin. Adv Exp Med Biol 2008; 625: 33-47.
364. Batista D da G, Batista MM, de Oliveira GM. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment. Antimicrob Agents Chemother 2010; 54(7): 2940-52.
365. Bukrinsky, M.I., Cerami, A., Ulrich, P., Berger, B. Compounds and methods of use to treat infectious diseases. US6906076 (2005).
366. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. Acidocalcisomes-conserved from bacteria to man. Nat Rev Microbiol 2005; 3(3): 251-61.
367. Lang, H.J., Lanzer, M., Wiesner, J., Sanchez, C, Wunsch, S.E.P. Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa. US6114393 (2000).
368. Montalvetti A, Rohloff P, Docampo RA. A functional aquaporin co-localizes with the vacuolar proton pyrophosphatase to acidocal-cisomes and the contractile vacuole complex of Trypanosoma cruzi. J Biol Chem 2004; 279(37): 38673-82.
369. Beitz E. Aquaporins from pathogenic protozoan parasites: Structure, function and potential for chemotherapy. Biol Cell 2005; 97(6): 373-83.
370. Rohloff P, Docampo R. A contractile vacuole.complex is involved in osmoregulation in Trypanosoma cruzi. Exp Parasitol 2008; 118(1): 17-24. Review
371. Landfear SM. Drugs and transporters in kinetoplastid protozoa. Adv Exp Med Biol 2008; 625: 22-32.
372. Schoijet AC, Miranda K, Girard-Dias W, de Souza W, Flawiá MM, Torres HM, et al. A Trypanosoma cruzi phosphatidylinositol 3-kinase (TcVps34) is involved in osmoregulation and receptor-mediated endocytosis. J Biol Chem 2008; 283(46): 31541-50.
373. 2+-sensitive soluble exopolyphospha-tase from Trypanosoma cruzi depletes polyphosphate and affects osmoregulation. J Biol Chem 2007; 282(44): 32501-10.
374. Moreira OC, Rios PF, Esteves FF, Meyer-Fernandes JR, Barrabin H. CrATP as a new inhibitor of ecto- ATPases of Trypanosomatids. Parasitology 2009; 136(1): 35-44.
375. Einicker-Lamas M, Nascimento MT, Masuda CA, Oliveira MM, Caruso-Neves C. Trypanosoma cruzi epimastigotes: regulation of myo-inositol transport by effectors of protein kinases A and C. Exp Parasitol 2007; 117(2): 171-7.
376. Inbar E, Canepa GE, Carrillo C, Glaser F, Suter Grotemever M, Rentsch D, et al. Lysine transporters in human trypanosomatid pathogens. Nucleosides Nucleotides Nucleic Acids 2009; 28(5): 473-84.
377. Boutaleb-Charki S, Marín C, Maldonado CR, Rosales MJ, Urbano J, Gutierrez-Sancez R, et al. Copper (II) complexes of [1,2,4]triazolo [1,5-a]pyrimidine derivatives as potential antiparasitic agents. Drug Metab Lett. 2009; 3(1):35-44.
378. D'Angelo MA, Sanguineti S, Reece JM, Birnbaumer L, Torres HN, Flawiá MM. Identification, characterizati on and subcellular localization of TcPDE1, a novel cAMP-specific phosphodiesterase from Trypanosoma cruzi. Biochem J 2004; 378: 63-72.
379. Schoijet AC, Miranda K, Medeiros LC, de Souza W, Flawiá MM, Torres HN, et al. Defining the role of a FYVE domain in the localization and activity of a cAMP phosphodiesterase implicated in osmoregulation in Trypanosoma cruzi. Mol Microbiol 2011; 79(1): 50-62.
380. King Keller S, Li M, Smith A, Zheng S, Kaur G, Yang X, et al. Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease. Antimicrob Agents Chemother 2010; 54(9): 3738-45.
381. Michels PA, Bringaud F, Herman M, Hannaert V Metabolic functions of glycosomes in trypanosomatids. Biochim Biophys Acta 2006; 1763(12):1463-77.
382. Wilkinson SR, Prathalingam SR, Taylor MC, Horn D, Kelly JM. Vitamin C biosynthesis in trypanosomes: a role for the glycosome. Proc Natl Acad Sci USA 2005; 102(33): 11645-50.
383. Ferella M, Montalvetti A, Rohloff P, Miranda K, Fang J, Reina S, et al. A solanesyl-diphosphate synthase localizes in glycosomes of Trypanosoma cruzi. 2006; 281(51): 39339-48.
384. Menna-Barreto RF, Gonçalves RD, Costa EM, Silva RS, Pinto AV, Oliveira MF, et al. The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. Free Radic Biol Med. 2009; 47(5): 644-53.
385. Matsuo AL, Silva LS, Torrecilhas AC, Pascoalino BS, Ramos TC, Rodrigues EG, et al. In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother 2010; 54(8):3318-25.
386. Boiani L, Aguirre G, González M, Cerecetto H, Chidichimo A, Cazzulo JJ, et al. Furoxan-, alkylnitrate-derivatives and related compounds as anti-Trypanosomatid agents: mechanism of action. Bioorg Med Chem 2008; 16(17): 7900-07.
387. Menna-Barreto RF, Laranja GA, Silva MC, Coelho MG, Paes MC, Oliveira MM, et al. Anti-Trypanosoma cruzi activity of Pterodon pubescens seed oil: geranylgeraniol as the major bioactive component. Parasitol Res 2008; 103(1): 111-7.
388. Andreu PGL, Inada NM, Pellón RF, Docampo ML, Fascio ML, D'Accorso NB, et al. In vitro effect of a new cinnamic acid derivative against the epimastigote form of Trypanosoma cruzi. Arznei-mittelforschung 2009; 59(4): 207-11.
389. Menna-Barreto RF, Henriquez-Pons A, Pinto AV, Morgado-Diaz JA, Soares MJ, De Castro SL. Effect of a beta-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles. J Antimicrob Chemother 2005; 56(6): 1034-41.
390. Schenkman S, Chaves LB, de Carvalho PLC, Eichinger D. A proteolytic fragment of Trypanosoma cruzi trans-sialidase lacking the carboxyl-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity. J Biol Chem 1994; 269(11): 7970-75.
391. Frasch AC. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol Today 2000; 16(7): 282-6.
392. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM. The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell 2002; 10(4): 757-68.
393. Streicher H, Busse H. Building a successful structural motif into sialylmimetics cyclohexenephosphonate monoesters as pseudo-sialosides with promising inhibitory properties. Bioorg Med Chem 2006; 14 (4): 1047-57.
394. Horenstein, B.A.; Parr, I.B. Neuraminidase inhibitors. WO9906369 (1999).
395. Luo, M.; White, C.L. Inhibitors of bacterial sialidase. US6114386 (2000).
396. Carvalho I, Andrade P, Campo VL. 'Click chemistry' synthesis of a library of 1, 2, 3-triazole-substituted galactose derivatives and their evaluation against Trypanosoma cruzi and its cell surface trans-sialidase. Bioorg Med Chem 2010; 18(7): 2412-27.
397. Pierdominici-Sottile, Roitberg AE. Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Biochemistry 2011; 50(5): 836-42.
398. Santa-Rita SM, Barboza SH, Meirelles MN, de Castro SL. Effect of the alkyl lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 2000; 75 (2): 219-28.
399. Lira R, Contreras LM, Rita RM, Urbina JA. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 2001; 47(5): 537-46.
400. de Castro SL, Santa-Rita RM, Urbina JA, Croft SL. Antiprotozoal lysophospholipid analogues: a comparison of their activity against Trypanosomatid parasites and tumor cells. Mini Rev Med Chem 2004; 4(2): 141-51.
401. Santa Rita RM, Lira R, Barbosa HS, Urbina JA, de Castro SL. Anti-proliferative synergy of lysophospholipid analogues and keto-conazole against Trypanosoma cruzi (Kinetoplastida: Trypanoso-matidae): Cellular and ultrastructural analysis. J Antimicrob Che-mother 2005; 55(5): 780-84.
402. Santa RRM, Barbosa HS, de Castro SL. Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypano-soma cruzi. Parasitol Res 2006; 100(1): 189-90.
403. Jones SM, Urch JE, Brun R, Harwood JL, Berry C, Gilbert IH. Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents. Bioorg Med Chem 2004; 12(4): 683-92.
404. Couto AS, Caffaro C, Uhrig ML, Kimura E, Peres VJ, Merino EF, et al. Glycosphingolipids in Plasmodium falciparum. Presence of an active glucosylceramide synthase. Eur J Biochem 2004; 271(11): 2204-14.
405. Pankova-Kholmyansky I, Flescher E. Potential new antimalarials chemotherapeutics based on sphingolipid methabolism. Chemotherapy 2006; 52: 205-9.
406. Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther 2010; 4: 243-53.
407. Cerecetto H, Gonzalez M. Synthetic medicinal chemistry in Cha-gaśdisease: Compounds at the final stage of "hit-to-lead" phase. Pharmaceuticals 2010; 3: 810-38.
408. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115(1-2): 55-68.
409. McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson SA, Ferreira R, et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1):263-9.
410. Engel JC, Ang KKH, Chen S, Aekin MR, McKerrow JH, Doyle PS. Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease. Antimicrobial Agents Chemotherap 2010; 54(8): 3326-34.